Technology Transfer Office Information For:
 
 


POC Grant Program (POCg; Founded 2005)

This program is inactive until 2012.

In the fall of 2005, a research funding program was initiated – the Proof of Concept grant program (POCg). The POCg provides awards to enable pilot stage development and validation of CU inventions that have promising prospects for commercialization. For example, three categories of disclosures for which a relatively small amount of research funding may yield a dramatic increase in value for the invention are:

  • Advancement of hypothesis testing - test an idea or in silico prediction with in vitro experiments, extend in vitro results with in vivo experiments, or build a bench prototype;
  • Target validation – screen small molecule libraries, produce antibodies, or select target-binding peptides or aptamers; and
  • Pre-commercial research – validate academic software code for commercial application, drug formulation, or develop alternative applications for technology.

In order to apply for a POCg award (as a pre- or co-requisite) an invention disclosure for the subject technology must be on file with the TTO.  POCg awards can range from $10-25K, and the technologies are selected by a competitive application process. Proposals are reviewed by the TTO, and each award is deposited directly into a CU research account. POCg has funded 58 projects, with the following outcomes:


pie

TTO Contact

  • For questions and assistance concerning the POCg or application process and criteria, please contact Kate Tallman (Kate.Tallman@cu.edu, 303-492-5732) if you are an inventor from the Boulder or Colorado Spring campuses, and please contact Rick Silva (Rick.Silva@cu.edu, 303-724-0222) if you are an inventor from the Downtown Denver or Anschutz Medical campuses.
  • For questions and assistance concerning the POCi program or application process and criteria, please contact: Tom Smerdon, Director of New Business Development, at tom.smerdon@cu.edu or 303-735-0621.

NOTE: THIS PROPOSAL WILL NOT BE MADE PUBLIC, EXCEPT FOR A NON-CONFIDENTIAL EXECUTIVE SUMMARY.